A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs GX 188E (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Acronyms GX-188E-FU
- Sponsors Genexine
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2018.
- 11 Jul 2017 Planned primary completion date changed from 31 Aug 2017 to 1 Jan 2018.